Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

68 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Treatment algorithm for metastatic renal cell carcinoma--recommendations based on evidence and clinical practice.
Bergmann L, Beck J, Bothe K, Brinkmann OA, Buse S, Goebell PJ, Grünwald V, Holzapfel K, Kübler H, Marschner NW, Mickisch G, Schultze-Seemann W, Siebels M, Siemer S, Störkel S, Gschwend JE. Bergmann L, et al. Among authors: siebels m. Oncol Res Treat. 2014;37(3):136-41. doi: 10.1159/000360179. Epub 2014 Feb 21. Oncol Res Treat. 2014. PMID: 24685918 Free article.
Interleukin-2- and interferon alfa-2a-based immunochemotherapy in advanced renal cell carcinoma: a Prospectively Randomized Trial of the German Cooperative Renal Carcinoma Chemoimmunotherapy Group (DGCIN).
Atzpodien J, Kirchner H, Jonas U, Bergmann L, Schott H, Heynemann H, Fornara P, Loening SA, Roigas J, Müller SC, Bodenstein H, Pomer S, Metzner B, Rebmann U, Oberneder R, Siebels M, Wandert T, Puchberger T, Reitz M; Prospectively Randomized Trial of the German Cooperative Renal Carcinoma Chemoimmunotherapy Group (DGCIN). Atzpodien J, et al. Among authors: siebels m. J Clin Oncol. 2004 Apr 1;22(7):1188-94. doi: 10.1200/JCO.2004.06.155. Epub 2004 Feb 23. J Clin Oncol. 2004. PMID: 14981107 Clinical Trial.
Interleukin-2/interferon-alpha2a/13-retinoic acid-based chemoimmunotherapy in advanced renal cell carcinoma: results of a prospectively randomised trial of the German Cooperative Renal Carcinoma Chemoimmunotherapy Group (DGCIN).
Atzpodien J, Kirchner H, Rebmann U, Soder M, Gertenbach U, Siebels M, Roigas J, Raschke R, Salm S, Schwindl B, Müller SC, Hauser S, Leiber C, Huland E, Heinzer H, Siemer S, Metzner B, Heynemann H, Fornara P, Reitz M. Atzpodien J, et al. Among authors: siebels m. Br J Cancer. 2006 Aug 21;95(4):463-9. doi: 10.1038/sj.bjc.6603271. Epub 2006 Aug 8. Br J Cancer. 2006. PMID: 16909131 Free PMC article. Clinical Trial.
Immunotherapy in metastatic renal cell carcinoma.
Rohrmann K, Staehler M, Haseke N, Bachmann A, Stief CG, Siebels M. Rohrmann K, et al. Among authors: siebels m. World J Urol. 2005 Jul;23(3):196-201. doi: 10.1007/s00345-004-0470-4. Epub 2005 Apr 2. World J Urol. 2005. PMID: 15806434 Review.
Phase 1 trial of allogeneic gene-modified tumor cell vaccine RCC-26/CD80/IL-2 in patients with metastatic renal cell carcinoma.
Buchner A, Pohla H, Willimsky G, Frankenberger B, Frank R, Baur-Melnyk A, Siebels M, Stief CG, Hofstetter A, Kopp J, Pezzutto A, Blankenstein T, Oberneder R, Schendel DJ. Buchner A, et al. Among authors: siebels m. Hum Gene Ther. 2010 Mar;21(3):285-97. doi: 10.1089/hum.2008.192. Hum Gene Ther. 2010. PMID: 19788391 Clinical Trial.
68 results